| Home | Community | Message Board |
|
You are not signed in. Sign In New Account | Forum Index Search Posts Trusted Vendors Highlights Galleries FAQ User List Chat Store Random Growery » |

This site includes paid links. Please support our sponsors.
|
| Shop: |
| |||||||
|
Registered: 07/26/04 Posts: 19,263 |
| ||||||
Auto-SummaryA recent survey study published in the Journal of Psychoactive Drugs explores a unique cognitive paradox: why psychedelic experiences often feel profoundly familiar despite being entirely new. By comparing psychedelic trips to autobiographical memories and episodes of déjà vu, researchers found that substances like DMT and psilocybin trigger a sense of "familiarity" that is more intense, comforting, and transcendent than everyday recognition. While recollection relies on the hippocampus to retrieve specific details, psychedelics may uncouple the brain's sense of recognition from actual memory retrieval, potentially by stimulating serotonin 2A receptors in the outer cerebral cortex. This distinction is significant because many users report that this feeling of "coming home" to strange or spiritual realms leads to lasting emotional or spiritual shifts. Although researchers caution against interpreting these subjective sensations as literal evidence of external realms, they suggest that understanding this unique psychological profile could be vital for improving clinical psychedelic therapy and advancing broader cognitive science research. Psychedelics trigger a bizarre memory paradox that makes the unknown feel like home November 17, 2026 - PsyPost People who take psychedelic substances often report an intense feeling of familiarity, as though they are reconnecting with a state or place they have known before, even when their surroundings feel strange and new. A survey study published in Journal of Psychoactive Drugs suggests that this psychedelic-evoked familiarity has a distinct subjective profile that sets it apart from cherished personal memories and everyday episodes of déjà vu. Most respondents viewed the sensation as genuine and comforting, and roughly half reported lasting emotional or spiritual shifts tied to it, pointing to an understudied feature of psychedelic experiences that could matter in clinical settings. In cognitive science, memory for lived events relies on two separate mental processes: recollection and familiarity. Recollection, which depends heavily on a deep brain structure called the hippocampus, involves retrieving specific details about when and where an event happened. Familiarity, handled largely by surrounding regions of the outer cerebral cortex, is the standalone sense of recognizing something as previously encountered without retrieving any specific context, like recognizing a face on a bus without knowing where you met. Classic psychedelics such as psilocybin (the active compound in “magic mushrooms”), lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) act primarily by stimulating serotonin 2A receptors in the brain. Alongside vivid imagery and a dissolving sense of self, these substances typically make perceptions feel strikingly novel, yet users paradoxically describe a powerful sense of returning somewhere deeply familiar, even on their first trip. “The question came up while we were coding nearly 3,800 DMT trip reports for an earlier study,” study lead author David Wyndham Lawrence, an associate professor in the Temerty Faculty of Medicine and director of sport and exercise medicine in the Faculty of Kinesiology and Physical Education at the University of Toronto, told PsyPost. “People described impossibly complex geometric patterns, encounters with seemingly autonomous beings, and worlds where time and space seemed to work differently. What struck me most was what sometimes came next.” “After describing these extraordinary experiences, people would say they felt as though they’d been there before, that it felt like coming home, or that they somehow already knew the beings they’d encountered,” Lawrence said. “I kept coming back to that paradox. How could something so far removed from ordinary experience feel so deeply familiar?” Psychoactive drugs can pull recollection and familiarity in opposite directions while memories are forming. In an earlier laboratory experiment with healthy adults co-authored by Manoj K. Doss of the University of Texas at Austin Dell Medical School, one of the researchers on the new paper, taking psilocybin or a synthetic psychedelic called 2C-B reduced participants’ accuracy at recalling details of neutral and positive images while making them more likely to falsely feel that new, emotionally charged pictures were familiar. Without drugs, familiarity arises in contrasting ways during everyday life: autobiographical memories bring warm recognition rooted in personal history, such as visiting a childhood home, whereas déjà vu produces an eerie flash of familiarity paired with the knowledge that the situation is new. To examine how psychedelic familiarity compares with both states and help prepare patients in clinical trials, Lawrence, who is also affiliated with Mount Sinai Hospital in Toronto, conducted a comparative survey with Doss and Akira Robert O’Connor of the University of St Andrews. Between November 2024 and February 2025, the researchers recruited English-speaking adults through email and social media platforms including Reddit, X, Discord, Instagram, and Facebook. Out of 1,420 people who opened the anonymous survey, 1,050 completed data for at least one condition: a psychedelic trip, a familiar everyday memory, or a typical episode of déjà vu. Respondents were predominantly male (76.4%) and white (77.0%), living mostly in the United States or Canada, and the exploratory study’s dataset is available from the authors upon request. In the psychedelic section, completed by 868 participants (800 with prior psychedelic use), respondents reported their use of classic psychedelics such as psilocybin, LSD, DMT, ayahuasca, and mescaline. They also reported any use of related psychoactive compounds, including 5-MeO-DMT (a potent chemical relative of DMT), salvinorin A (from the plant Salvia divinorum), the dissociative anesthetic ketamine, and 3,4-methylenedioxymethamphetamin Those who had felt familiarity on a psychedelic rated the single trip where it was strongest, reporting the drug, dose, setting, perceived authenticity, and any lasting effects. Separately, 679 participants completed the autobiographical section by rating a familiar everyday place or event. Another 605 completed the déjà vu section, with the 575 who had experienced déjà vu rating a typical episode. For each experience, participants completed the 19-item Sense of Familiarity Questionnaire on a scale from 0 (“not at all”) to 5 (“extreme, more than any other time in my life”). The items measure feelings of comfort, nostalgia, belonging, and remembering, alongside transcendent themes such as encountering a familiar entity or visiting an eternal realm that feels like a home for consciousness. Respondents also rated emotional intensity, comfort, novelty, strangeness, and anxiety from 1 to 7, with statistical models accounting for participants who evaluated multiple experiences. Among participants with a history of psychedelic use, 91.5% reported feeling familiarity during at least one trip, including 41 individuals who experienced it the first time they ever took a psychedelic. Familiarity was reported most often by users of DMT (75.8%) and psilocybin (63.0%), followed by roughly half of LSD, ayahuasca, and 5-MeO-DMT users, and between one-fifth and three-tenths of MDMA, mescaline, salvinorin A, and ketamine users. When identifying the single substance that evoked their strongest sense of familiarity, respondents most frequently named DMT (34.7%) and psilocybin (31.3%). Most of these episodes took place at home during medium or large self-reported doses. Among respondents who reported timing, 95.5% said the familiarity arose during the trip itself rather than upon later reflection, and 75.9% of those who specified a stage placed it at the peak. Across the group, participants most often attached the familiarity to their conscious state (69.2%) or emotions rather than physical objects. Participants who had experienced both drug-induced and everyday forms of familiarity also compared them directly. Among those who answered these head-to-head questions, 84.9% rated their psychedelic familiarity as more profound than their chosen autobiographical memory, and 82.5% rated it as more profound than everyday déjà vu. Across all 19 questionnaire items, psychedelic experiences likewise scored higher than both autobiographical memories and déjà vu. The widest gap appeared on transcendent items, such as visiting an infinite realm, a place beyond birth and death, or a home for consciousness, where psychedelic trips had median scores of 4 or 5 while personal memories and déjà vu both had medians of 0. Statistical models estimated a 49.3% to 58.2% probability that a psychedelic trip would earn the maximum rating on those transcendent items, compared with 0.1% or less for the non-drug states. Even on everyday warmth items such as “feels like home,” models estimated a 51.8% probability of a top score for psychedelic trips, nearly double the 27.9% estimate for personal memories like childhood homes. Déjà vu rarely felt like home (4.1%), scoring lower than autobiographical memories on belonging and welcoming feelings, though higher on the raw sensation of remembering something forgotten. On the 1-to-7 emotional ratings, psychedelic familiarity combined high comfort with high strangeness and novelty. Psychedelic trips received a median comfort score of 7, surpassing both autobiographical memories (6) and déjà vu (4), while matching déjà vu on strangeness and novelty and exceeding personal memories on both. Differences in anxiety across the three experience types were not statistically significant, with scores remaining low overall. “From the individual reports, we already had a sense of what psychedelic familiarity could feel like,” Lawrence noted. “What surprised me was how clearly it stood out when we looked at the survey responses together.” “Compared with déjà vu and meaningful personal memories, people rated their psychedelic experiences as more familiar and more novel, as well as more emotionally intense and more comforting,” he continued. “That combination is what I keep coming back to. Something can feel deeply familiar even as it feels entirely new.” Responses also differed across drug classes, though the non-classic subgroups were small, ranging from 16 to 32 respondents compared with 607 for classic psychedelics. Classic psychedelics scored higher on comfort and welcoming feelings than salvinorin A, which produced greater strangeness than MDMA and slightly higher anxiety than ketamine. Classic psychedelics, 5-MeO-DMT, and salvinorin A all evoked a stronger sense of remembering something forgotten than ketamine did, and 5-MeO-DMT scored much higher than MDMA on transcendent items, whereas drug-group differences in emotion and novelty were not statistically significant. Most respondents who rated the nature of their psychedelic familiarity perceived it as an authentic reconnection rather than a drug illusion (82.9%). Nearly nine in ten (85.7%) reported that it positively shaped their trip, compared with 2.7% who reported a negative effect. Just over half of those who answered a follow-up item (52.8%) reported enduring changes from the familiarity, describing emotional transformation, interconnectedness, altered views of reality, spiritual awakening, and greater comfort with mortality. These findings align with an earlier analysis of online DMT trip reports led by Lawrence, which also used the Sense of Familiarity Questionnaire and found that profound familiarity arose independently of prior psychedelic use alongside mystical states and ego dissolution, grouping into broader and entity-centered patterns. That earlier study examined existing Reddit posts restricted to DMT, whereas the new research directly surveyed users across multiple psychedelic substances and everyday non-drug experiences. To account for how psychedelic states can feel novel and deeply familiar at once, the authors suggest that these drugs may uncouple the brain’s sense of recognition from actual memory retrieval. They also point to an alternative explanation within a single trip: because classic psychedelics boost familiarity-based memory encoding, impressions formed early in a session could feel intensely familiar later in the same trip and be mistaken for older memories. “But why it occurs remains an open question,” Lawrence explained. “One possibility is that changes in how the brain processes information during a psychedelic experience make parts of it feel unusually vivid or easy to take in, and that the brain interprets that vividness or ease as a sign of recognition.” Although the study did not measure brain activity, the researchers propose that the distribution of serotonin 2A receptors may play a role, since these receptors excite outer cortical regions involved in familiarity while activating inhibitory cells in deep memory structures like the hippocampus. Drawing on the mere exposure effect, the tendency for familiar things to feel likable and safe, the authors suggest that this welcoming recognition could help patients feel grounded during psychedelic therapy and support post-session integration. There are a few things to keep in mind when interpreting these findings, including author disclosures. Study co-author Doss serves as an advisor to VCENNA and receives research support from the Heffter Research Institute, the Center for MINDS, the Effie and Wofford Cain Foundation, and the Alice Kleberg Reynolds Foundation. The findings also require caution when respondents describe visiting realms beyond birth and death. Treating a vivid altered state of consciousness as an actual journey to another plane of reality is a pitfall that scientists studying psychedelics warn against. “We want to be transparent here, because this topic invites overinterpretation and what I’ve called ‘ontological tourism’ (I published a separate editorial on it partly as a check on my own interpretive biases),” Lawrence cautioned. “When people describe familiarity with an eternal place or somewhere beyond death, that reflects how the experience felt, not evidence that such a place exists. Our data also don’t show that psychedelics or this feeling improve mental health.” Because respondents were recruited through social media and online psychedelic communities and were largely experienced male users, individuals with vivid or positive familiarity experiences were likely much more inclined to participate, meaning the high prevalence here does not reflect all people who take psychedelics. Seeing explicit side-by-side comparisons between psychedelic trips and everyday states may also have cued participants to rate drug experiences more strongly, a survey bias known as demand characteristics. The comparisons across conditions carried built-in asymmetries as well. Participants picked their single strongest psychedelic familiarity episode, with 42.6% recalling a trip from over a year earlier, and rated it on a scale originally built from DMT reports whose entity and transcendent items naturally yield near-zero scores for everyday memories and déjà vu. In addition, drug doses were self-estimated rather than standardized, and subgroups for compounds such as MDMA and 5-MeO-DMT included fewer than 20 respondents each. Addressing these gaps will require controlled prospective trials that administer standardized doses and track participants’ experiences in real time. “Psychedelics give us a unique way to separate the feeling of familiarity from actual memory (recollection), which could provide an avenue to advance broader memory research and our understanding of how the brain generates that feeling in everyday life,” Lawrence added. “Our survey also suggests that familiarity contributes to what makes these experiences feel positive and meaningful. If the subjective experience turns out to matter for therapeutic benefit, that could make familiarity a feature worth understanding, and perhaps cautiously supporting, in clinical settings.” The study, “Characterizing Psychedelic-Evoked Familiarity: A Comparative Study with Autobiographical and Déjà Vu Experiences,” was authored by David Wyndham Lawrence, Manoj K. Doss, and Akira Robert O’Connor.
| |||||||
| |||||||
| Shop: |
|
| Similar Threads | Poster | Views | Replies | Last post | ||
![]() |
Discover Magazine article on psychedelics | 7,843 | 5 | 03/23/03 09:05 AM by DazedSol | ||
![]() |
Are psychedelic drugs good for you? | 8,228 | 6 | 12/03/03 06:44 AM by sirreal | ||
![]() |
Sacred Sexuality and the Psychedelic Experience | 17,454 | 3 | 02/22/09 02:02 AM by veggie | ||
![]() |
LSD doctor dies | 5,623 | 4 | 02/22/04 02:03 PM by motaman | ||
![]() |
Drug task force is making mark | 1,601 | 0 | 03/31/04 10:27 AM by Anno | ||
![]() |
Police seize psychedelic mushroom stash | 4,011 | 8 | 08/17/04 09:30 AM by Cyber | ||
![]() |
Student charged with selling psychedelic mushrooms | 5,761 | 2 | 05/15/03 01:50 PM by JssMthrFcknChrst | ||
![]() |
Judge Makes Ruling in Peyote Case | 5,073 | 10 | 04/29/03 03:33 PM by Anonymous |
| Extra information | ||
| You cannot start new topics / You cannot reply to topics HTML is disabled / BBCode is enabled Moderator: motaman, veggie, Alan Rockefeller, Mostly_Harmless 21 topic views. 1 members, 19 guests and 10 web crawlers are browsing this forum. [ Show Images Only | Sort by Score | Print Topic ] | ||

